FMP
IMARA Inc.
IMRA
NASDAQ
Inactive Equity
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
6.32 USD
0.87 (13.77%)
About
ceo
Dr. Rahul D. Ballal Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://imaratx.com
exchange
NASDAQ
Description
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
CIK
0001672619
ISIN
US45249V1070
CUSIP
45249V107
Address
116 Huntington Avenue
Phone
617 206 2020
Country
US
Employee
41
IPO Date
Mar 12, 2020
Summary
CIK
0001672619
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45249V107
ISIN
US45249V1070
Country
US
Price
6.32
Beta
1.08
Volume Avg.
116.26k
Market Cap
165.8M
Shares
-
52-Week
0.9739-6.32
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
105.33
P/B
-
Website
https://imaratx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest IMRA News
It looks like there's no news available.
